This is an open label, phase I study assessing the safety and tolerability of a pharmaceutical formulation comprising a protein that is being developed as a treatment for acute ischemic stroke.
Eligible participants will be required to stay in the clinical unit for a total of 4 nights and 5 days.
Participants must meet the following criteria:
Male or Female between the ages of 18 and 50
BMI must be between 18 – 30 kg/m2
Medication free with no allergies to any drugs
Free from any clinically significant illness or disease as determined by medical history
Remuneration is offered to eligible participants.
Click here to register for our clinical trials.